Randomized Phase II study of multi-peptide vaccination and bispecific PSMAxCD3 antibody treatment in patients with biochemical relapse of prostate cancer

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522144-41-00

Enrollment

Registered

2026-07-20

Start date

Unknown

Completion date

Unknown

Last updated

2026-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

biochemical relapse of prostate cancer

None listed

Sex/Gender

Male

Age

18 Years to No maximum

None listed

Source: EU CTIS · Data processed: Jul 21, 2026